Bharat Biotech To Scale Up Covaxin Production To 1 Billion Doses Per Year

Bharat Biotech's announcement, which comes amid several states complaining of vaccine shortage, effectively takes the total volume of doses to nearly a billion per year.

Bharat Biotech on Thursday said it's planning to ramp up the manufacturing capacity of its COVID-19 vaccine, Covaxin, by an additional 200 million doses per year, the vaccine maker said in a statement. The announcement, which comes amid several states complaining of vaccine shortage, effectively takes the total volume of doses to nearly a billion per year. The vaccine maker has ramped up the manufacturing capacity at its subsidiary's Ankleshwar (Gujarat) based facility. "The company plans to produce 200 million doses of Covaxin per year in its GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety," Bharat Biotech said. The Ankleshwar-based plant would start rolling out the much in demand vaccine from the fourth quarter of the year, it added.